Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BIEL: HUGE HIT IN TAIWAN!
https://www.actipatchtw.com/general-1
AI Edge Computing: The Big Three starting to rip....$BZAI on fire...Low floaters $GSIT & $OSS about to go orbital.
$OSS: Link
https://finviz.com/quote.ashx?t=OSS&p=d
$GSIT: Link
https://gsitechnology.com/
AI Edge Computing: $OSS low floater Earnings out in a few weeks. Likely sterling numbers and big growth. Drum beat will certainly get louder in coming sessions. Link:
https://onestopsystems.com/
nkla.....muln............................................................................https://stockcharts.com/h-sc/ui?s=muln&p=D&yr=0&mn=2&dy=12&id=p84071410134
$NIPG News: NIP Group Forms Strategic Partnership with Optics Valley Traffic Company to Launch Digital Entertainment Hub in Wuhan
Tue, February 11, 2025
News Link:
https://finance.yahoo.com/news/nip-group-forms-strategic-partnership-133000684.html
AI Edge Computing: Investors are finding the AI Edge Sector via $OSS....Once $OSS goes big, AI Edge low float chip play $GSIT will go with it....$GSIT has $RGTI type move in it.
BIEL: HUGE VA NEWS - Flagship product RecoveryRX now available to all veterans at all VA's!
Ted Fienning
BioElectronics Corporation
Harvard University
Marine Corp Pilot
"Share with any veteran you know using the VA: RecoveryRX is an FDA-approved pain management device now available nationwide at every VA. Non-opioid, non-invasive, and available by asking your VA provider."
https://kellycovemobility.com/rrx/
An American hero gives a fantastic testimonial about Bioelectronics flagship product - RecoveryRX!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174980584
AI EDGE COMPUTING SECTOR: $OSS wants to break out here. Getting found in same way investors for $RGTI & $QUBT when the Quantum Sector got discovered.
AI Edge play $GSIT also likely to get very hot all at once.
Best advice. Load up on both $OSS & $GSIT and be there when the very large crowds arrive....Awareness already building.
#DDAmanda Video: $IVVD: Gain: +204% #1 Early Alert Stock Finder
MITQ.....MOBX......MBOT......MULN.......................https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=3&dy=0&id=p11960084343
BIEL: WORLDWIDE EXPANSION UNDERWAY!!!
New Zealand:
https://www.actipatch.nz/
Huge hit in Taiwan!
https://www.actipatchtw.com/general-1
BIEL WILL CREATE BIELIONAIRES!
AI Edge Computing: The Sector leader right now is $OSS. They have US Military contracts with likely NASA and SpaceX contracts in pipeline. Whatever other stock one chooses in the Sector, $OSS is a must own.
Many now are likening $OSS to the Quantum Sector 1500% ripper $RGTI. Few investors ever heard of Quantum stocks but within weeks became a market obsession. So too with stocks like $QUBT.
So, load up on $OSS for sure and $GSIT , as well.
The AI Edge Computing goldrush is just starting.
What was formerly a Sector dominated only by $PLTR now has other members.
BIEL + DR. OZ + RFK = $$$
BIOELECTRONICS FLAGSHIP PRODUCT - ACTIPATCH - ON DR. OZ:
Dr. Oz devoted a whole program to explaining PEMF Pulsed ElectroMagnetic Field technology - with audience members wearing Actipatches (BIEL's flagship product) - saying it is changing the practice of medicine.
https://www.facebook.com/share/v/18NzZcGQVm
May be great AHs play...$MI @ $2.90s: Total shares 700K.. Float 300K (Tightly held)...Has $122.00 cash a share...If you missed the $DXF $2 to $140 here is your second chance.,$MI Getting found on awful market day Monday. Has all week to orbit shot.
$OSS: AI Edge Computing leader. Low floater. NASA & SpaceX contracts in pipeline. Already has US Military contracts. Cash rich. All American Made.
Tons of $NVDA & $ORCL cash looking for a Sector like AI Edge Computing. Unaffected by DeepSeek controversy.
Very much like $MTEK & $SPCB before they went vertical.
https://onestopsystems.com/
$NRXP News: HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Engage BTIG as Financial Advisor
HOPE has announced plans to assemble a best-in-class global network of interventional psychiatry clinics combining ketamine treatment with transcranial magnetic stimulation, and digital therapeutics to treat severe depression and PTSD
BTIG is a leading global financial services firm specializing in investment banking, institutional trading, research, and related brokerage services
Advisory to include identification and evaluation of clinic partners and strategic assets and investment banking services in connection with financing initiatives to accelerate the Company's business plan
MIAMI, Feb. 3, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx", and collectively with HOPE, the "Company") (Nasdaq:NRXP), today announced engagement of BTIG, a leading global financial services firm specializing in investment banking, institutional trading, research and related brokerage services. The scope of the engagement includes advisory and assistance in evaluating strategic and financing options available to the Company and identification, evaluation and negotiation of potential acquisition targets for the HOPE network of clinics, as well as equity and debt financing structures.
The Company has recently announced execution of an agreement for $27 million in funding for HOPE Clinic Acquisition. Upon closing of the first tranche of the anticipated financing, the Company currently intends to leverage the investment with proposed bank debt and similar instruments to fund its initial rollup of Interventional Psychiatry Clinics. The Company has now engaged BTIG to advise the Company on clinical partners to acquire and to facilitate acquisition capital financing.
"We are excited to partner with NRx and HOPE to accelerate the Company's business strategy of assembling a global network of Interventional Psychiatry Clinics," said Robert Dentice, Managing Director Investment Banking, BTIG. "Addressing the mental health crisis in this country and abroad is a vital need which we are honored to help address."
"We are pleased to engage with BTIG to build our HOPE network and work to establish HOPE as a leading provider of world-class care for patients suffering from suicidal depression, PTSD and related conditions," said Jonathan Javitt, MD MPH and Matthew Duffy, Co-CEOs of HOPE Therapeutics. "BTIG is exceptionally well positioned to propel HOPE to achieve our goals, and we look forward to working with the firm to execute on our plan."
The information in this press release is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities in any jurisdiction pursuant to the proposed transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
About BTIG
BTIG is a global financial services firm specializing in investment banking, institutional trading, research and related brokerage services. With an extensive global footprint and more than 700 employees, BTIG, LLC and its affiliates operate out of 20 cities throughout the U.S., and in Europe, Asia and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs and fixed income, currency and commodities. The firm's core capabilities include global execution, portfolio, electronic and outsource trading, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a development stage healthcare delivery company that intends to develop a best-in-class network of interventional psychiatry clinics to offer ketamine transcranial magnetics stimulation (TMS) and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the consummation of the $27 million in financing necessary to consummate the acquisitions of Hope's clinics, entering into binding documentation necessary to consummate the acquisitions, and the Company's ability to raise equity or debt financing. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including the risk that the transactions contemplated by the LOI are not consummated, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, HOPE Therapeutic's ability to consummate the acquisitions of providers for its national network, the Company's ability to raise adequate capital to fund such acquisitions, and the Company's ability to spin-off HOPE Therapeutics. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-Chief Executive Officer, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
https://c212.net/c/img/favicon.png?sn=CL10019&sd=2025-02-03 View original content to download multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-engage-btig-as-financial-advisor-302366415.html
SOURCE NRx Pharmaceuticals, Inc.
$AAGC New Video conference call highlights!
https://x.com/nickeli54/status/1885838457357889584?s=46&t=Cx3eH5ebwLlhhItIhOgIvg
$SSSS: Owns OpenAI stock. Going to rip when OpenAI opens new Funding Round next week. Valuation of OpenAI has doubled. Link:
Own $SSSS and own OpenAI
Website: Click on Portfolio link in upper right. Some great AI names includiong OpenAI
https://surocap.com/
OpenAI Funding Round news:
https://www.cnbc.com/2025/01/30/openai-in-talks-to-raise-up-to-40-billion-at-340-billion-valuation.html
$NRXP News: HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition
$25 million investment in HOPE to consist of Series A (non-dilutive to NRx shareholders) convertible into 1/3 of fully diluted HOPE equity, with a 15% current preferred dividend (non-callable for 2 years) for planned HOPE clinic acquisitions
Initial funding of $2.0 million for purchase of NRx common stock anticipated to close on or before January 29, with the first tranche of $6.75 million of $25.0 million investment to be invested in HOPE Therapeutics, Inc. on or before February 7, 2025, and the balance of $18.25 million by April 1, 2025
Funds will be used in conjunction with anticipated bank financing to initiate nationwide rollup strategy of interventional psychiatry clinics, starting with Kadima Neuropsychiatry (La Jolla, CA)
HOPE intends to initiate nationwide acquisition program in partnership with leading investment bank on or around February 1, 2025.
MIAMI, Jan. 28, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx", and collectively with HOPE, the "Company") (Nasdaq:NRXP), today announced the signing and of a Stock Purchase Agreement ("SPA") with Smith & Sauer, LLC, as the first step in a $27.0 million financing to fund the planned acquisition of HOPE clinics. The agreement signed today provides for the immediate funding of $2.0 million in NRx common stock and commits Smith and Sauer to purchase an additional $25 million in newly issued Series A Preferred Stock of HOPE, the proceeds of which are intended to be used to initiate a nationwide rollup of Interventional Psychiatry Clinics to treat patients with severe, suicidal depression and PTSD. The first $6.75 million tranche is committed by February 7, 2025, with the full $25 million committed on or before April 1, 2025.
The Company anticipates leveraging the Smith and Sauer investment with bank debt and similar instruments to fund an initial rollup of Interventional Psychiatry Clinics with anticipated revenues of approximately $100 million on a pro-forma basis by the end of 2025. Unlike "ketamine clinics" that are frequently operated by non-mental health professionals, HOPE anticipates building a best-in-class nationwide chain of facilities that combine treatment with ketamine and other psychedelic medications with Transcranial Magnetic Stimulation (TMS) and recently FDA-approved Digital Therapeutics to best serve patients with life-threatening depression, PTSD, and related disorders.
"Today's transaction caps several months of intensive work as we have identified best-in-class interventional psychiatry clinics and assembled the capital from both Anson Funds and Smith and Sauer to consummate the initial acquisitions. The resources committed today are anticipated to bring the Company to the $100 million revenue threshold. We have initiated a financial advisory relationship with a leading investment bank to assemble the next $400 million of capital required to build a national and international presence," said Jonathan Javitt, MD MPH Chairman of NRx Pharmaceuticals. "Psychedelic Medications such as ketamine, neuromodulation technologies such as TMS, and digital therapeutics have sparked a revolution in psychiatry where for the first time patients with life threatening conditions such as depression and PTSD hope for a brighter future. As we develop HOPE Therapeutics, we aim to bring that future to the 16 million Americans who consider ending their lives each year and the 45 million Americans who suffer from depression and PTSD."
"We are honored to partner with NRx and HOPE to tackle the pressing mental health challenges facing our nation, particularly within the military and veteran communities," said Dallas Sauer, Co-Founder of Smith & Sauer.
"This partnership underscores the critical importance of addressing mental health with innovative and accessible solutions," said Anita Nunes, Co-Founder of Smith & Sauer. "We are proud to support HOPE and NRx in their mission to bring transformative care to underserved communities, including our veterans and military families."
Readers are advised to consult the Current Report on Form 8-K that NRx intends to file with the Securities and Exchange Commission on or before January 31, 2025 for a complete description of the Stock Purchase Agreement Although no assurances can be given, closing of the additional $25 million investment in HOPE's Series A Preferred Stock remains subject to execution of definitive agreements and the satisfaction of standard closing conditions.
The information in this press release is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities in any jurisdiction pursuant to the proposed transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
About Smith & Sauer
Founded by Dallas Sauer and Anita Nunes, Smith & Sauer, LLC is a private investment firm specializing in strategic partnerships and capital investments across healthcare, technology, and emerging industries. With decades of experience in operational leadership, financial structuring, and technological innovation, Smith & Sauer is committed to fostering growth in mission-driven organizations. The firm's investment philosophy centers on long-term value creation, aligning financial performance with societal impact. By leveraging its expertise in health information technology and clinic integration, Smith & Sauer plays a pivotal role in advancing cutting-edge solutions to address critical healthcare challenges.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a development stage healthcare delivery company that intends to develop a best-in-class network of interventional psychiatry clinics to offer ketamine transcranial magnetics stimulation (TMS) and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the satisfaction of closing conditions necessary to consummate the acquisition of Kadima and Dura, and obtaining financing necessary to consummate the acquisitions. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including the risk that the transactions contemplated by the LOI are not consummated, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, HOPE Therapeutic's ability to consummate the acquisitions of providers for its national network, the Company's ability to raise adequate capital to fund such acquisitions, and the Company's ability to spin-off HOPE Therapeutics. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-Chief Executive Officer, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
https://c212.net/c/img/favicon.png?sn=CL05942&sd=2025-01-28 View original content to download multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-execute-agreement-for-27-million-funding-transaction-for-hope-clinic-acquisition-302361736.html
SOURCE NRx Pharmaceuticals, Inc.
AI EDGE COMPUTING: $OSS. Key sector play with rock solid volume. Getting found in same way Quantum crowd found $RGTI and $QUBT....$OSS is a partner w/ giant $PLTR and also the US Army among many others....Owning $OSS here as AI Edge Computing gets found is a huge money maker. Load up on low floater $OSS.
BIEL 911 FINAL TRADE, NEWS TOMORROW? GOLDEN CROSS BREAKOUT!
$IVDN: Record Sales Growth for Patented, “Evacuated Cell” Insulation Delivering Superior R-6 Rating & Other Advanced Specs to Meet New Government Building Codes: Innovative Designs, Inc. (Stock Symbol: IVDN)
January 13, 2025
Very Small Stock Structure of Only 38 Million OS / 16 Million Float
LINK:
https://markets.financialcontent.com/bostonherald/article/getnews-2025-1-13-record-sales-growth-for-patented-evacuated-cell-insulation-delivering-superior-r-6-rating-and-other-advanced-specs-to-meet-new-government-building-codes-innovative-designs-inc-stock-symbol-ivdn
• Sole Maker of Patented Insultex® Insulation Delivering Construction Cost and Energy Saving Performance Superior to All Competition.
• Unique Evacuated Cell House Wrap Material Provides an Unmatched R-6 Rating, Water Vapor, Air & Wind Barrier and Other Important Advantages.
• 2024 Fiscal Third Quarter Revenues More Than Doubled Same Period in 2023.
• First Nine Months of Fiscal 2024 Delivered a 285% Increase Over 2023.
• Accelerating Order Flow and Record Backlog in 2024 vs. No Backlog in 2023.
• New Government Building Codes Require Continuous Insulation with Higher Performance and IVDN Meets or Exceeds These Standards Where Many Competitors Now Do Not.
• Increased Order Fulfilment Capabilities Recently Added with Plans for Further Enhancement to Handle Increasing Demand.
• Greater Energy Savings from Insultex® Insulation Delivers Economic Gains & Tax Credits for the User and Carbon Reduction for the Environment.
mitq.......mobx......mbot........muln.........................................https://stockcharts.com/h-sc/ui?s=muln&p=D&yr=0&mn=2&dy=12&id=p84071410134
$TORVF ~ Why Volt Carbon Invested in E Power Resources $TORVF & $VCT Stock
https://www.youtube.com/watch?v=U0MtiNs5z2Q
$DATS ripping...$MITQ @ .70s: Float 6.3M w/$5.2M cash. No debt. Sector peer of red hot $DATS...$MITQ low hanging fruit this week for the micro-float launch crews.
The truly spooky munitions shortage for the Pentagon: Silver bullets https://breakingdefense.com/2024/10/the-truly-spooky-munitions-shortage-for-the-pentagon-silver-bullets/
BIEL + DR. OZ + RFK = $$$
BIOELECTRONICS FLAGSHIP PRODUCT - ACTIPATCH - ON DR. OZ:
Dr. Oz devoted a whole program to explaining PEMF Pulsed ElectroMagnetic Field technology - with audience members wearing Actipatches (BIEL's flagship product) - saying it is changing the practice of medicine.
https://www.facebook.com/share/v/18NzZcGQVm
ABAT.....LDTC.,...MKZR.....RR.....AMPX.....CTOR.................https://stockcharts.com/h-sc/ui?s=ABAT&p=D&yr=0&mn=3&dy=0&id=p11960084343
BIEL: NEWS COMING!
https://recoveryrx1.carrd.co/
$BLIS is looking good to start off the new year. Tax loss selling time is done and the company has major prospects for revenue growth coming up in the immediate term, as well covered on the latest news. This is certainly a stock to watch in 2025.
NAPC Defense (OTCPK: BLIS) issues new Progress Report regarding Large Contract with Saudi Arabia, Live-Fire Demos for U.S. based Police and SWAT, Manufacturing update, and more
LARGO, Fla., Dec. 12, 2024 (GLOBE NEWSWIRE) -- NAPC Defense, Inc., (OTCPK: BLIS) (“NAPC” or “the Company”) announces that the Company is making strong progress on its CornerShot USA weapons systems and other initiatives.
NAPC’s Management believes the Company is well positioned to drive significant revenue and profits in 2025, from its own manufacturing and sale of CornerShot in the United States and Saudi Arabia. NAPC maintains it will also drive revenue through the brokering of arms and munitions, as well as contract work for renovation and clean up, following recent hurricanes in the area.
As previously announced, NAPC received a signed and stamped Letter of Intent from Saudi Arabia for an initial order of 37,000 CornerShot units, valued at (U.S.) $370 million. Management has already conducted critical late-stage meetings and live-fire demonstrations in Saudi Arabia with several military divisions through visits to the country in August and October of 2024.
NAPC Defense has now received a request to complete live fire demonstrations in Saudi Arabia from Saudi Land Forces. The visit is planned to take place between December 29, 2024 and January 12, 2025. The Company previously reported that this upcoming visit would take place last month.
Please see below for a list of current and anticipated NAPC developments, as we enter the New Year:
Following the next phase of the upcoming CornerShot demonstrations in Saudi Arabia, NAPC expects that it will enter final contract negotiations, deposit funding, and initial CornerShot manufacturing. in Q1 of 2025.
NAPC has secured manufacturing facilities for the production of CornerShot USA weapons systems in Pinellas Park, FL. The space is large enough to meet anticipated demand for the near future.
Live-fire demonstrations were recently conducted for St. Petersburg Police and SWAT teams in Pinellas County. New orders from these departments, as well as others, are expected in January 2025.
NAPC Defense has secured booth space #10953 at the upcoming SHOT Show in Las Vegas from January 21-24, 2025. The SHOT Show is the largest and most comprehensive trade show for all professionals involved with the shooting sports, hunting and law enforcement industries.
In addition to over $1.5 million in new hurricane renovation and cleanup work in Pinellas Country, the Company has partnered with another firm in an effort to win an additional $3 million in contracts.
CEO Kenny West stated, “This is truly an exciting time for NAPC Defense. We have laid the groundwork in 2024, and now it’s time to deliver in 2025. We appreciate the ongoing support from our shareholders and investors.”
About NAPC Defense, Inc.
NAPC Defense, Inc. https://www.napcdefense.com/ is an armament sales and production company, fully licensed in the United States, with exclusive rights to produce and sell CornerShot USA weapons systems in the U.S and Saudi Arabia, in addition to brokering arms and munitions throughout the world all with US State Department approval. Additional smaller weapons platforms, a series of ballistics protection technologies and related products are in development or being finalized for sale.
FORWARD LOOKING STATEMENTS:
This press release and the statements of representatives of NAPC (the "Company") related thereto contain, or may contain, among other things, "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact included herein are "forward-looking statements," including any other statements of non-historical information.
These forward-looking statements are subject to significant known and unknown risks and uncertainties and are often identified by the use of forward-looking terminology such as "guidance," "projects," "may," "could," "would," "should,’ “believes," "expects," "anticipates,” “estimates," "intends," "plans, “ultimately" or similar expressions. All forward-looking statements involve material assumptions, risks and uncertainties, and the expectations contained in such statements may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results (including, without limitation, NAPC's ability to advance its business, generate revenue and profit and operate as a public company) could differ materially from those stated or anticipated in these forward-looking statements as a result of a variety of factors, including factors and risks discussed in the periodic reports that the Company files with the SEC. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. The Company undertakes no duty to update these forward-looking statements except as required by law.
COMPANY CONTACT:
Kenny West, CEO (754) 242-6272 Ext.713
https://www.globenewswire.com/newsroom/ti?nf=OTMxODA3MiM2NjM0MDk5IzIyNjE1MDY=
https://ml.globenewswire.com/media/ZTE0MTNkZDEtNzcyMi00YmU0LTk2YTEtMThmMDA4NDI4NGEwLTEyNzMwNTY=/tiny/NAPC-Defense-Inc-.png
BIEL: HUGE VA NEWS - Flagship product RecoveryRX now available to all veterans at all VA's!
Ted Fienning
BioElectronics Corporation
Harvard University
Marine Corp Pilot
"Share with any veteran you know using the VA: RecoveryRX is an FDA-approved pain management device now available nationwide at every VA. Non-opioid, non-invasive, and available by asking your VA provider."
https://kellycovemobility.com/rrx/
An American hero gives a fantastic testimonial about Bioelectronics flagship product - RecoveryRX!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174980584